OPSONA & LONZA enter into manufacturing agreement for the production of a monoclonal antibody OPN-305 developed by OPSONA Therapeutics Ltd.
Read more on OPSONA Therapeutics Ltd & LONZA manufacturing agreement.
For further information on Opsona please contact:
Dr Mark Heffernan CEO
Tel: + 353 (01) 8968499
Email: info@opsona.com
Dr Jeremy Skillington
Senior Director of Business Development
Tel: + 353 1 8968499
Info: info@opsona.com